Patents Assigned to Levo Therapeutics, Inc.
-
Patent number: 11957656Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).Type: GrantFiled: October 26, 2020Date of Patent: April 16, 2024Assignees: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Inc.Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L Leibel, Sara Cotter
-
Publication number: 20230201300Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: ApplicationFiled: February 21, 2023Publication date: June 29, 2023Applicant: LEVO THERAPEUTICS, INC.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant
-
Publication number: 20230014640Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: March 2, 2022Publication date: January 19, 2023Applicant: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 11298399Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: November 18, 2021Date of Patent: April 12, 2022Assignee: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Publication number: 20220072086Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: ApplicationFiled: November 18, 2021Publication date: March 10, 2022Applicant: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 11207373Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.Type: GrantFiled: September 20, 2019Date of Patent: December 28, 2021Assignee: LEVO THERAPEUTICS, INC.Inventors: Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
-
Patent number: 10967040Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: GrantFiled: July 24, 2020Date of Patent: April 6, 2021Assignee: Levo Therapeutics, Inc.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
-
Patent number: 10842775Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).Type: GrantFiled: June 2, 2017Date of Patent: November 24, 2020Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, LEVO THERAPEUTICS, INC.Inventors: Lisa Cole Burnett, Dieter Egli, Rudolph L. Leibel, Sara Cotter
-
Publication number: 20200353029Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.Type: ApplicationFiled: July 24, 2020Publication date: November 12, 2020Applicant: Levo Therapeutics, Inc.Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
-
Publication number: 20190298686Abstract: The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).Type: ApplicationFiled: June 2, 2017Publication date: October 3, 2019Applicants: The Trustees of Columbia University in the City of New York, Levo Therapeutics, Incs, Inc.Inventors: Lisa Cole BURNETT, Dieter EGLI, Rudolph L. LEIBEL, Sara COTTER